Filing Flows › Whitehawk Therapeutics (WHWK) › Q1 2025
Whitehawk Therapeutics (WHWK) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Whitehawk Therapeutics (WHWK) reported revenue of $7.1M for the first quarter 2025 (Q1 2025), +33% from a year earlier and -1% from the quarter before. Operating margin was -213.0%.
Whitehawk Therapeutics, Q1 2025: revenue $7.1M (+34% year over year), operating margin -213.0%, net earnings $73.0M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.1M | -1% | +33% |
| Operating profit | −$15.2M | — | — |
| Net earnings | $73.0M | — | — |
| Operating cash flow | −$11.9M | — | — |
What changed
Revenue was $7.1M in Q1 2025, up 33% year over year and down 1% from the previous quarter.
Operating costs exceeded revenue by $15.2M, an operating margin of -213.0%. Total costs fell 10% while revenue rose 33%. The fastest-growing cost line was SG&A (+21%). Net earnings were $73.0M. The effective tax rate was 0.0%. Non-operating items added $88.2M, 121% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$11.9M. Non-cash charges added back $57K of depreciation and $1.7M of share-based compensation. Working capital and other items used $86.6M. Capital expenditures of $551K exceeded it, leaving free cash flow of −$12.4M.
Questions
What was Whitehawk Therapeutics' revenue in the first quarter 2025?
Whitehawk Therapeutics (WHWK) reported revenue of $7.1M for the first quarter 2025 (Q1 2025), +33% from a year earlier and -1% from the quarter before.
Was Whitehawk Therapeutics profitable in the first quarter 2025?
Operating loss was $15.2M (-213.0% of revenue) and net earnings $73.0M.